CYP in Medical Technology

Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.

Michael S. Singer, M.D., Ph.D. Contributing Editor Harvard Medical School The FDA approval of BiDil for heart failure in African American patients has underscored the concept that two patients can respond differently to the same medication. This concept holds true for a wide variety of ...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

...he active metabolite. Approximately 30 percent of Caucasians and 60 percent of Asians have reduced function in the CYP2C19 gene, which is part of the cyp system and encodes the enzymes that are responsible for converting prasugrel into its active form(2). In the substudy, researchers examined how v...

Clinical Update - Debio 025 in Hepatitis C

...rates the onset of action and enhances efficacy in the early stage of treatment. About Debio 025 Debio 025 is a synthetic first-in-class cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication ad...

Clinical Update - Debio 025 in Hepatitis C

...eatment which we hope to address," added Kamel Besseghir, CEO of Debiopharm S.A. About Debio 025 Debio 025 is a synthetic first-in-class cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication ad...

Clinical Update - Debio 025 in Hepatitis C

.... "This unique mechanism of action is the first alternative treatment to classic HCV therapies." Debio 025 Debio 025 is a synthetic first-in-class cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication ad...

Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment of HCV

...ohort with the highest dose in the protocol," said Kamel Besseghir, CEO of Debiopharm S.A. About Debio 025 Debio 025 is a synthetic first-in-class cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to cyclophilins, host cell proteins thought to confer a repli...

Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimer's Drug

...esired potentially toxicity or pharmacologically inactive metabolites. In addition, positive results were reported where SP-233 was shown to have no cyp inhibition potential for CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 suggesting that SP-233, is unlikely to cause, or alter the metabolism of co-admini...

Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

...and potent activity in HCV replicon assays. The compound also displayed very good in vitro metabolic stability and did not significantly inhibit human cyp enzymes, suggesting a low potential for drug-drug interactions. Extending these in vitro findings, in vivo preclinical studies of ANA598 demonstrated ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

...lack, Asian, and other racial groups. Drug Interactions In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of cyp isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

...lack, Asian, and other racial groups. Drug Interactions In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of cyp isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a p-glycoprotein substrate, but does not inhibit p...